Investigational drug · Phase 2
AZD0516
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Prostate Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "AZD0516"
First trial start
2025
Oct 1, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD0516", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Prostate Cancer
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD0516" as an intervention, largest first.
- Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate CancerPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07181161 · 283 participants (planned) · Start Oct 1, 2025 · Primary completion Jan 18, 2029
Drug: AZD0516; AZD9574 · For: Metastatic Prostate Cancer
Sites: Fayetteville, Arkansas; Los Angeles, California; Towson, Maryland · 52 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Metastatic Prostate Cancer
- PalacaparibAZD9574Phase 25 trials
AstraZeneca · Metastatic Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- FPI-2265AZD2265, 225Ac-PSMA-I&TPhase 24 trials
Fusion Pharmaceuticals Inc. · Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Metastatic Castration Resistant Prostate Cancer
- BalstilimabAGEN2034Phase 23 trials
ImmunoGenesis · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
- AZD2287Imaging agentPhase 22 trials
AstraZeneca · Metastatic Prostate Cancer
- ZalifrelimabPhase 22 trials
ImmunoGenesis · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
- AZD0754Phase 21 trial
AstraZeneca · Metastatic Prostate Cancer
- AZD8359Phase 21 trial
AstraZeneca · Metastatic Prostate Cancer
- GDC-1261Phase 21 trial
Roche (Genentech) · Advanced Prostate Cancer, Metastatic Prostate Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.